# A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Study · id `cardio:ct-nct05013229` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05013229](<https://clinicaltrials.gov/study/NCT05013229>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05013229

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 679 participants.

## Technical summary

Registry record NCT05013229. Randomized; no masking; primary purpose treatment. Start 2021-11-30 (actual); primary completion 2023-11-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 679 participants (enrolled count; ClinicalTrials.gov record NCT05013229, source copy `cardio:ctgov-nct05013229-2025-12-02`, retrieved 2026-10-26)
- Started: 2021-11-30 (actual) (ClinicalTrials.gov record NCT05013229, source copy `cardio:ctgov-nct05013229-2025-12-02`, retrieved 2026-10-26)
- Primary completion: 2023-11-14 (actual) (ClinicalTrials.gov record NCT05013229, source copy `cardio:ctgov-nct05013229-2025-12-02`, retrieved 2026-10-26)
- Completion: 2023-11-14 (actual) (ClinicalTrials.gov record NCT05013229, source copy `cardio:ctgov-nct05013229-2025-12-02`, retrieved 2026-10-26)
- Countries: United States; Czechia; France; Germany; Hungary; India; Italy; Japan; Malaysia; Poland; Slovenia; South Africa; Thailand; Türkiye (ClinicalTrials.gov record NCT05013229, source copy `cardio:ctgov-nct05013229-2025-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05013229-2025-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): IcoSema
- Intervention (Drug): Insulin glargine
- Intervention (Drug): insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial (`cardio:pubmed-40482670`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fcd4cd6714d6f56bdd8078432a1f03bc96fce22e00774baf8ba9ff2e568bdd29
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
